Neurocrine Biosciences Inc (NBIX)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $16.94B
Last updated: Nov 17, 2026 at 11:05 AM ET
Neurocrine Biosciences Inc (NBIX) P/E Ratio & Valuation History
Neurocrine Biosciences (NBIX) trades at 18.4x trailing earnings and 4.5x sales. Its P/E of 18.4x is below its 5-year median of 24.7x. Its forward P/E is 16.4x. The median P/E across 10 similar companies is 19.7x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 12.2% higher over the next year. Its free cash flow yield is 6.2%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 18.4x |
| Forward P/E | 16.4x |
| Price to sales | 4.5x |
| Price to book | 4.3x |
| EV/EBITDA | 16.9x |
| Price to FCF | 16.2x |
| EV/FCF | 15.6x |
| PEG | 0.3 |
| FCF yield | 6.2% |
Historical Medians
Against its 10-year medians, its P/S is 47.1% below 8.5x and its P/B is 38.6% below 7.0x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/E | 18.4x | 24.7x | N/A |
| P/S | 4.5x | 6.1x | 8.5x |
| P/B | 4.3x | 5.4x | 7.0x |
Valuation History
Over the 8 of the 10 year ends shown that have a P/E, its P/E ranged from 21.6x in 2024 to 420.1x in 2018.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $141.83 | 22.2x | 5.0x | 4.5x |
| 2024 | $136.50 | 21.6x | 5.9x | 5.4x |
| 2023 | $131.76 | 34.5x | 6.9x | 6.0x |
| 2022 | $119.44 | 34.5x | 7.8x | 7.0x |
| 2021 | $85.17 | 47.3x | 7.1x | 5.9x |
| 2020 | $95.85 | 23.3x | 8.6x | 8.3x |
| 2019 | $107.49 | 325.7x | 12.7x | 16.4x |
| 2018 | $71.41 | 420.1x | 14.5x | 14.2x |
| 2017 | $77.59 | N/A | 43.6x | 19.3x |
| 2016 | $38.70 | N/A | 111.8x | 10.7x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About NBIX
What is NBIX's forward P/E ratio?
Neurocrine Biosciences has a forward P/E ratio of 16.4x.
Is NBIX stock overvalued?
GNG's valuation label for NBIX is Undervalued. Its P/E of 18.4x compares with a median of 19.7x across 10 similar companies.
What is NBIX's price to sales ratio?
Neurocrine Biosciences has a price to sales ratio of 4.5x.
What is Neurocrine Biosciences's average P/E ratio over 5 years?
Neurocrine Biosciences's median P/E over the last 5 years is 24.7x, from 60 month-end values through Oct 2026.
What is NBIX's PEG ratio?
Neurocrine Biosciences has a PEG ratio of 0.3.
NBIX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors